Skip to the beginning of the images gallery

Abrocitinib (PF-04965842) - 97%, high purity , CAS No.1622902-68-4, Inhibitor of Janus kinase 1;Inhibitor of Janus kinase 2

Moligand™
≥97%

CAS#: 1622902-68-4
Formula: C₁₄H₂₁N₅O₂S
Molecular Weight: 323.41
EC Number: 817-215-8
PubChem CID: 78323835

Item Number

A414165

Grouped product items
SKU	Size	Availability	Price
A414165-5mg	5mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$227.90
A414165-10mg	10mg	In stock	$401.90
A414165-25mg	25mg	In stock	$726.90
A414165-50mg	50mg	In stock	$1,162.90
A414165-100mg	100mg	In stock	$1,860.90

JAK2 Selective Inhibitors

View related series

Janus kinase 1 Inhibitor Janus kinase 2 Inhibitor

Basic Description

Synonyms	Abrocitinib\|1622902-68-4\|PF-04965842\|Cibinqo\|N-[cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl]propane-1-sulfonamide\|Abrocitinib [USAN]\|73SM5SF3OR\|CHEMBL4101725\|PF-04965842 (Abrocitinib)\|N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)ami
Specifications & Purity	97%
Storage Temp	Store at -20°C
Shipped In	Ice chest + Ice pads
Grade	Moligand™
Action Type	INHIBITOR
Mechanism of action	Inhibitor of Janus kinase 1;Inhibitor of Janus kinase 2
Product Description	Information PF-04965842 is a potentJAK1inhibitor with IC50s of 29 nM, 803 nM, > 10 000 nM and 1250 nM for JAK1, JAK2, JAK3 and tyrosine kinase (TYK) 2, respectively. Targets JAK1 (Cell-free assay); JAK2 (Cell-free assay); TYK2 (Cell-free assay) 29 nM; 803 nM; 1.253 μM In vivo Physicochemical properties and pharmacokinetic parameters of PF-04965842 are examined in rats following doses of 1 mg/kg iv or 3 mg/kg po. Clearance of PF-04965842 is low relative to total liver blood flow (CL = 26.6 mL/min/kg). Vdss = 1.04 L/kg. T_1/2 = 1.1 h. The oral availability of PF-04965842 is 95.6%. PF-04965842 demonstrates efficacy in a dose-responsive manner in a therapeutic rat adjuvant-induced arthritis model.

Associated Targets

JAK1 Tclin Tyrosine-protein kinase JAK1 1 Activities

Discover Target: JAK1

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

JAK2 Tclin Tyrosine-protein kinase JAK2 1 Activities

Discover Target: JAK2

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Names and Identifiers

IUPAC Name	N-[3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl]propane-1-sulfonamide
INCHI	InChI=1S/C14H21N5O2S/c1-3-6-22(20,21)18-10-7-11(8-10)19(2)14-12-4-5-15-13(12)16-9-17-14/h4-5,9-11,18H,3,6-8H2,1-2H3,(H,15,16,17)
InChi Key	IUEWXNHSKRWHDY-UHFFFAOYSA-N
Canonical SMILES	CCCS(=O)(=O)NC1CC(C1)N(C)C2=NC=NC3=C2C=CN3
Isomeric SMILES	CCCS(=O)(=O)NC1CC(C1)N(C)C2=NC=NC3=C2C=CN3
Alternate CAS	1622902-68-4
PubChem CID	78323835
MeSH Entry Terms	1-Propanesulfonamide, N-(cis-3-(methyl-7H-pyrrolo(2,3-d)pyrimidin-4-ylamino)cyclobutyl)-;abrocitinib;N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-1-propanesulfonamide;N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)
Molecular Weight	323.41

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

4 results found

Lot Number	Certificate Type	Date	Item
J2214453	Certificate of Analysis	Jul 19, 2024	A414165
J2214477	Certificate of Analysis	Jul 19, 2024	A414165
J2214483	Certificate of Analysis	Jul 19, 2024	A414165
J2214576	Certificate of Analysis	Jul 19, 2024	A414165

Safety and Hazards(GHS)

Pictogram(s)	GHS08
Signal	Warning
Hazard Statements	H361:Suspected of damaging fertility or the unborn child
Precautionary Statements	P280:Wear protective gloves/protective clothing/eye protection/face protection. P405:Store locked up. P501:Dispose of contents/container to ... P203:Obtain, read and follow all safety instructions before use. P318:if exposed or concerned, get medical advice.
RIDADR	NONHforallmodesoftransport

References

1. Schmieder GJ, Draelos ZD, Pariser DM, Banfield C, Cox L, Hodge M, Kieras E, Parsons-Rich D, Menon S, Salganik M et al.. (2018) Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study.. Br J Dermatol, 179 (1): (54-62). [PMID:28949012]
2. Vazquez ML, Kaila N, Strohbach JW, Trzupek JD, Brown MF, Flanagan ME, Mitton-Fry MJ, Johnson TA, TenBrink RE, Arnold EP et al.. (2018) Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.. J Med Chem, 61 (3): (1130-1152). [PMID:29298069]
3. Silverberg JI, Simpson EL, Thyssen JP, Gooderham M, Chan G, Feeney C, Biswas P, Valdez H, DiBonaventura M, Nduaka C et al.. (2020) Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.. JAMA Dermatol, 156 (8): (863-873). [PMID:32492087]
4. Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, Bieber T, Thyssen JP, Yosipovitch G, Flohr C et al.. (2020) Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.. Lancet, 396 (10246): (255-266). [PMID:32711801]

Solution Calculators

Molarity Calculator

Determine the necessary mass, volume, or concentration for preparing a solution.

Dilution Calculator

Determine the dilution needed to prepare a stock solution.